Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof

Patent metadata

Field	Value
Publication number	US-9896455-B2
Application number	US-201615242928-A
Country	US
Kind code	B2
Filing date	Aug 22, 2016
Priority date	Aug 27, 2007
Publication date	Feb 20, 2018
Grant date	Feb 20, 2018

Abstract

The present invention provides tricyclic compounds having cytostatic and cytotoxic activity in a single molecule having receptor tyrosine kinase(s), dihydrofolate reductase, thymidylate synthase and/or dihydroorotate dehydrogenase inhibitory activity, which are useful as anti-angiogenic and anti-tumor agents. Also provided are methods of utilizing these inhibitors to treat tumor cells and other proliferative diseases and disorders.

First claim

What is claimed is:

1. A method of inhibiting receptor tyrosine kinase(s), dihydrofolate reductase, thymidylate synthase and/or dihydroorotate dehydrogenase activity in an animal or human in need thereof, comprising administering to said animal or human a therapeutically effective amount in unit dosage form of a compound of formula I:

wherein both B and C rings may be completely or partially saturated or unsaturated with respect to bond 4b-8a, 5-6 and 7-8; the C ring may have an N or substituted N depending on the saturation level of the C ring, and the substitution may be all of R 1 , R 2 and R 3 ; X and/or Y=NH, O, S, CH 2 ; P=(a) NR 4 , except that R 4 is not H, (b) O, or (c) CR 4 R 5 when the C ring has an N or a substituted N depending on the saturation level of the C ring and the substitution may be all of R 1 , R 2 , and R 3 ; wherein R 4 and R 5 =lower alkyl, alkene, alkyne, and all of R 1 and R 2 ;
R 1 =an alkyl having C 2 to C 6 , a cycloalkyl having 6 or less carbons, alkene, alkyne, aryl, heteroaryl, substituted aryl, substituted heteroaryl, alkylaryl, alkylheteroaryl, substituted alkylaryl or alkylheteroaryl, and R 1 may be H when said C ring is partially or completely saturated or partially unsaturated; and R 2 =H, an alkyl, a cycloalkyl having 6 or less carbons, alkene, alkyne, aryl, heteroaryl, substituted aryl, substituted heteroaryl, alkylaryl, alkylheteroaryl, substituted alkylaryl or alkylheteroaryl;
Z=S, O, NR 6 , S—CH 2 , CH 2 —S, O—CHR 6 , CHR 6 —O, NR 6 —CH 2 , CH 2 —NR 6 , CHR 6 —NR 7 or CR 6 R 7 , wherein R 6 and/or R 7 =H or a lower alkyl, alkene or alkyne having 6 or less C atoms;
wherein Z may be attached to the C ring at positions 5, 6, 7, or 8 and may be attached to more than one of said positions 5, 6, 7, or 8 on the ring, wherein Z may be the same or different;
wherein Z may be zero and R 3 may be directly attached to the C-ring at positions 5, 6, 7, and/or 8;
wherein when the C-ring is saturated or partially saturated the substituted Z or R 3 creates chirality when P=C and R 6 and R 7 are different, then all stereoisomers thereof both separately and as racemic and/or diastereoisomeric mixtures are included;
R 3 =H, alkyl, cycloalkyl, aryl, heteroaryl, substituted aryl, substituted heteroaryl, alkylaryl, alkylheteroaryl and substituted saturated or unsaturated alkylheteroaryl and alkylheterocyclic, alkylaryl, p-, m-, o-benzoyl-L-glutamate or 2,5-, 2,4-thienoyl-L-glutamate when the benzene and thiophene ring may or may not have additional substitutions including F, mono-, bi- and tricyclic aryl, heteroaryl or combinations thereof, ring substitutions including biphenyl, bipyridyl or a phenyl-pyridyl or a fused moiety including a quinoline or naphthyl including substituted systems including a 2-chloro,4-biphenyl and tricyclic and substituted tricyclic systems.

2. The method according to claim 1 , wherein Y=NH; R 2 =H; P=NR 4 ; R 4 =an alkyl having from 2 to 6 carbon atoms; X=NH; R 1 =[H] an alkyl group having from 2 to 6 carbon atoms (C 2 to C 6 ); Z=S, and R 3 =a phenyl.

3. The method according to claim 1 , wherein Y=NH; R 2 =H; P=NR 4 ; R 4 =an alkyl having from 2 to 6 carbon atoms; X=NH; R 1 =[H] an alkyl group having from 2 to 6 carbon atoms (C 2 to C 6 ); Z=S; and R 3 =a phenyl having a methyl substitution.

4. The method according to claim 3 , wherein the substitution on the phenyl is at the 4 position of the phenyl ring.

5. The method according to claim 1 , wherein the route of administration of the compound of formula I is parenteral, oral, or intraperitoneal.

6. The method according to claim 1 , wherein the route of administration is selected from the group consisting of intravenous; intramuscular; interstitial, intraarterial; subcutaneous; intraocular; intracranial; intraventricular; intrasynovial; transepithelial, including transdermal; pulmonary via inhalation; ophthalmic; sublingual; bucal; topical, including dermal, ocular, and rectal; and nasal inhalation via insufflation or nebulization.

7. The method according to claim 1 , wherein the unit dosage is administered orally in the form of hard or soft shell gelatin capsules, tablets, troches, sachets, lozenges, elixirs, suspensions, syrups, wafers, powders, granules, solutions or emulsions.

8. The method according to claim 1 , wherein the route of administration is a nasal administration of the compound of formula I that is selected from the group consisting of aerosols, atomizers and nebulizers.

9. The method according to claim 1 , wherein said animal or human is afflicted with a proliferative disease or disorder selected from the group consisting of leukemia, non-small cell lung cancer, colon cancer, central nervous system cancer, melanoma, ovarian cancer, renal cancer, prostate cancer, breast cancer; macular degeneration and retinopathies.

Assignees

• Duquesne Univ Of The Holy Ghost
• Univ Holy Ghost Duquesne

Inventors

• Gangjee Aleem

Classifications

• A61P35/02

  specific for leukemia · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C07D239/70

  condensed with carbocyclic rings or ring systems · CPC title

• C07D487/04 Primary

  Ortho-condensed systems · CPC title

• A61K31/517

  ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine · CPC title